Jérôme Rossert

AstraZeneca (United States) — United States

Medicine · Health Sciences

50h-index16.8kcitations163works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Kidney Disease and Diabetes(25), Renal Diseases and Glomerulopathies(24), Erythropoietin and Anemia Treatment(24), Dialysis and Renal Disease Management(17), Biosimilars and Bioanalytical Methods(15)

Publications161 total

Application of eGFR Thresholds as End Point Components in a Kidney Hierarchical Composite End Point
Journal of the American Society of Nephrology·2024
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
Journal of the American Society of Nephrology·2023· 29 citedOpen Access
Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review
Journal of the American Society of Nephrology·2023· 21 citedOpen Access
Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis
JAMA Network Open·2022· 38 citedOpen Access
Perioperative THR-184 and AKI after Cardiac Surgery
Journal of the American Society of Nephrology·2017· 44 citedOpen Access
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease
Kidney International Supplements·2017· 6 citedOpen Access
Genetic and environmental risk factors for chronic kidney disease
Kidney International Supplements·2017· 95 citedOpen Access
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
The Lancet·2017· 896 citedOpen Access
Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics
Analytical and Bioanalytical Chemistry·2016· 33 cited
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia
BMJ Open Diabetes Research & Care·2014· 54 citedOpen Access
Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test
Nephrology Dialysis Transplantation·2014· 96 citedOpen Access
Red Blood Cell Transfusions and the Risk of Allosensitization in Patients Awaiting Primary Kidney Transplantation
Transplantation·2013· 84 cited
Risk of Pure Red Cell Aplasia in Patients With Hepatitis C Receiving Antiviral Therapy and an Erythropoiesis-Stimulating Agent
Clinical Gastroenterology and Hepatology·2013· 4 cited
Sensitization from transfusion in patients awaiting primary kidney transplant
Nephrology Dialysis Transplantation·2013· 85 citedOpen Access
Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
American Journal of Kidney Diseases·2012· 21 cited
EGR1 and EGR2 Involvement in Vertebrate Tendon Differentiation
Journal of Biological Chemistry·2010· 206 citedOpen Access
Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes
New England Journal of Medicine·2010· 458 citedOpen Access
Acute Interstitial Nephritis
Elsevier eBooks·2010· 14 cited
Long‐Term Evolution and Determinants of Renal Function in HIV‐Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997–1999, ANRS CO8 APROCO‐COPILOTE
Clinical Infectious Diseases·2009· 8 citedOpen Access
A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia
New England Journal of Medicine·2009· 156 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Kai‐Uwe Eckardt(9), Nicole Casadevall(9), Andrew S. Levey(6), Marc Froissart(6), Adeera Levin(4), Josef Coresh(4), Bénédicte Stengel(4), C. Jacquot(4), Bruno Fouqueray(4), Dick de Zeeuw(3), Carol A. Pollock(3), Pascal Houillier(3), Heidi Eberspaecher(3), Benoît De Crombrugghe(3), Lucette Pelletier(3), Catherine Terraz(3), Norbert Lameire(2), Garabed Eknoyan(2), Neil R. Powe(2), David C. Wheeler(2)